ACRO Biomedical Co., Ltd.

🧬 Let's end the wait for donated tissues and organs Corneal blindness is one of the few kinds of blindness we can actually cure. And still, 20 million people live with it — because there is one donor cornea for every 70 who need one. The surgery exists. The tissue doesn't. At ACRO Biomedical, we believe the answer isn't more donors. It's a better scaffold. Our propreitary supercritical CO₂ decellularization platform removes cells and immunogens from natural tissue while leaving the collagen extracellular matrix fully intact — no harsh solvents, drastically reduced immune rejection, highly bio-equivalent. Welcome to visit us to know more about the platform and the product portfolio... 👁️ ABCcolla® Collagen Ophthalmic Matrix 💉 Regencoll® Collagen Implant 🩹 ABCcolla® Hemostatic Collagen Matrix 🧪 ABCcolla® Hemostatic ADM Paste ⚪ ABCcolla® Hemostatic ADM Scaffold 📍 BIO Asia–Taiwan 2026 · Booth M925, TaiNEX 1, 4F 📅 16–19 July · 10:00–18:00 (final day to 17:00) 🔗 www.acrobiomedical.com #BIOAsiaTaiwan2026 #RegenerativeMedicine #TissueEngineering #Biomaterials #Decellularization #MedTech #Ophthalmology #ACROBiomedical #Taiwan

# Reflections from BIO 2026: ACRO Biomedical Brings Regenerative Science to the World Stage Last week, our team had the privilege of joining global biotech ecosystem at the **BIO International Convention 2026** in San Diego (June 22–25). Driven by four days of intensive conversation, partnership-building, and a shared sense of purpose with ACRO Biomedical: turning rigorous science into real outcomes for patients. ## What we showcased... At the heart of our booth was **Hair Regeneration — Regenerative Miracle**, our latest application of ACRO's core collagen platform. The response from clinicians, distributors, and investors who stopped by was energizing, and it reaffirmed why we built this technology. A few of the highlights we shared with visitors: --> **Patented Collagen ADM Scaffold technology**, engineered to support hair follicle regeneration and scalp repair. --> A **dual-action approach** that pairs micro-needling with collagen delivery to encourage hair revival. - -> An **exclusive supercritical CO₂ extraction process** that ensures exceptional collagen purity, manufactured under **GMP-certified standards**. --> Recognition that backs the science — a **2024 Taiwan National Innovation Award**, supported by a portfolio of international patents and counting. Beyond hair regeneration, our conversations naturally extended to the broader ACRO platform — from collagen scaffolds and membranes to our regenerative matrices — and how this acellular, high-purity collagen technology can serve partners across ophthalmology, wound care, dental, and orthopedic applications. ## Thank you Our sincere thanks to the **Agricultural Technology Research Institute (ATRI)** for organizing the Taiwan delegation and creating a platform that let companies like ours stand shoulder to shoulder on the world stage. Thank you to DCB (Development Center for Biotechnology), Taiwan as well. And thank you to everyone who visited our booth, scanned our QR code, and traded ideas with our team — your questions made us sharper, and your enthusiasm reminded us why this work matters. ## Let's keep the conversation going We left San Diego with a full pipeline of follow-ups and a renewed conviction about where regenerative medicine is heading. If we connected at BIO 2026 — or if you wished we had — we'd welcome the chance to continue the discussion. ## Catch us next at BIO Asia–Taiwan 2026 The conversation doesn't end in San Diego — it continues on home turf. We'd love to welcome you to our booth at **BIO Asia–Taiwan 2026**, held **July 15–19 at the Taipei Nangang Exhibition Center (TaiNEX), Taipei**. If you'll be in Taipei, reach out and let's set up a meeting towards building the future of regenerative medicine together. **ACRO Biomedical Co., Ltd.** *Regenerative science, engineered for trust.* --- #BIO2026 #BIOAsiaTaiwan #Biotech #RegenerativeMedicine #HairRegeneration #CollagenTechnology #ATRI #TaiwanBiotech #ACROBiomedical #LifeSciences #MedTech

🎉 【Dr. Dar-Jen Hsieh, Founder and Chairman of ACRO Biomedical, Honored with the “Taiwan Medical Technology Contribution Award” at NATMA 2025 Annual Meeting】👁️ On October 18, 2025 (PDT), Dr. Dar-Jen Hsieh, Founder and Chairman of ACRO Biomedical, attended the North American Taiwanese Medical Association (NATMA) Annual Meeting in Los Angeles as the Keynote Speaker. During the event, he was honored with the “Taiwan Medical Technology Contribution Award”, recognizing his outstanding achievements in regenerative medicine. The previous recipient of this prestigious award was President Lai Ching-te, underscoring the honor’s significance and influence. Dr. Hsieh delivered a keynote address titled “A New Era of Regenerative Medicine,” sharing ACRO Biomedical’s innovative breakthroughs and global strategy in biomaterials and tissue regeneration. “It is a great honor to be invited by NATMA President Dr. David Yang to join so many distinguished physicians here in Los Angeles,” Dr. Hsieh said. “Receiving this meaningful award, especially knowing that President Lai Ching-te was the previous recipient, is both humbling and deeply motivating.” Founded in 1984, NATMA is one of the largest Taiwanese physician organizations in the United States, with chapters across the nation and the largest membership base in Southern California. The association is dedicated to fostering professional exchange among Taiwanese-American physicians, supporting both the Taiwanese and U.S. communities through free clinics, health seminars, scholarships, and medical collaborations that nurture the next generation of medical professionals. ACRO Biomedical has long been dedicated to developing advanced medical devices centered on natural collagen biomaterials. Utilizing its proprietary supercritical CO₂ decellularization technology, the company creates safe, biocompatible, and highly regenerative medical solutions used in ophthalmology, orthopedics, dentistry, aesthetic surgery, and wound care. Dr. Hsieh emphasized that the advancement of regenerative medicine requires continuous R&D investment, global collaboration, and rigorous clinical validation to ensure safety and efficacy. This award not only recognizes ACRO Biomedical’s technological excellence but also marks a significant milestone in promoting the internationalization of Taiwan’s medical innovation. #ACROBiomedical #NATMA #CornealRepair #OphthalmicMatrix #RegenerativeMedicine #MedicalInnovation

🌍 [ACRO Biomedical × Vietnam CT Group｜Official International Licensing Partnership Signed] 👁️ Following our partnership with OBM from Australia, ACRO Biomedical is proud to announce another exciting milestone: on July 26, we officially signed the agreement with CT Group, one of Vietnam’s leading national enterprises, to bring our ABCcolla® Collagen Ophthalmic Matrix to the 10 ASEAN countries. With over 33 years of history, CT Group is a strategic investor across 12 future-defining industries, including AI, semiconductors, renewable energy, quantum technology, and gene & cell therapy. The group operates nearly 70 affiliated companies worldwide. Led by Chairman Tran Kim Chung, the CT Group delegation visited Taiwan to formalize the partnership — a strong affirmation of confidence in ACRO’s regenerative medical technology. In the ASEAN region, more than 9 million people suffer from vision-related diseases, with corneal damage being a leading cause. However, access to effective treatment remains limited due to resource constraints. ACRO’s collagen ophthalmic matrix, developed using our proprietary supercritical CO₂ decellularization technology, provides a safe, stable, and ready-to-use regenerative solution: ✔ Supports tissue repair and regeneration ✔ Reduces the risk of immune rejection ✔ Eliminates reliance on human donors This collaboration marks a significant step in bringing Taiwan’s regenerative medicine to the global stage, and more importantly, brings visible hope to patients across Southeast Asia. #ACROBiomedical #CTGroup #InternationalPartnership #OphthalmicMatrix #RegenerativeMedicine #MedicalInnovation #ASEAN #VisionRestoration #SupercriticalCO2 #GlobalHealth #TaiwanBiotech

👁️ [Product Launch Success｜Opening a New Vision for Corneal Repair] 👁️ On July 24th, ACRO Biomedical proudly hosted the product launch event for ABCcolla® Collagen Ophthalmic Matrix during the BIO Asia–Taiwan Exhibition, officially announcing its approval by Taiwan's Ministry of Health and Welfare! 🎉 📖 Matthew 6:22-23 says: "The eye is the lamp of the body. If your eyes are healthy, your whole body will be full of light. But if your eyes are unhealthy, your whole body will be full of darkness." This verse reminds us that vision is not just about seeing — it’s about living with clarity, confidence, and hope. Globally, millions suffer from corneal diseases, yet only a fraction of patients receive timely corneal transplants due to donor shortages, long waiting times, and the risk of surgical complications. This unmet need calls for innovative solutions. ACRO Biomedical’s ABCcolla® Collagen Ophthalmic Matrix, developed using our proprietary supercritical CO₂ decellularization technology, offers a breakthrough approach to corneal repair: ✔ High safety – Decellularized porcine cornea reduces the risk of rejection and infection ✔ Excellent biocompatibility – Supports tissue regeneration and corneal healing ✔ Readily available – No reliance on human donors, enabling faster clinical response This milestone marks a shift from “waiting for transplants” to “immediate regenerative repair,” bringing new hope to those facing vision loss around the world. #ACROBiomedical #CornealRepair #RegenerativeMedicine #OphthalmicMatrix #corneatransplantation #MedicalInnovation #VisionRestoration #BIOAsiaTaiwan #SupercriticalCO2 #Matthew622